Vir Biotechnology (VIR) Competitors $7.15 +0.15 (+2.14%) Closing price 03/14/2025 04:00 PM EasternExtended Trading$7.16 +0.00 (+0.07%) As of 03/14/2025 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VIR vs. ACLX, ADMA, ZLAB, RNA, SWTX, RARE, IMVT, PTGX, SRRK, and AKROShould you be buying Vir Biotechnology stock or one of its competitors? The main competitors of Vir Biotechnology include Arcellx (ACLX), ADMA Biologics (ADMA), Zai Lab (ZLAB), Avidity Biosciences (RNA), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Immunovant (IMVT), Protagonist Therapeutics (PTGX), Scholar Rock (SRRK), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry. Vir Biotechnology vs. Arcellx ADMA Biologics Zai Lab Avidity Biosciences SpringWorks Therapeutics Ultragenyx Pharmaceutical Immunovant Protagonist Therapeutics Scholar Rock Akero Therapeutics Arcellx (NASDAQ:ACLX) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability. Do insiders and institutionals believe in ACLX or VIR? 96.0% of Arcellx shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 6.2% of Arcellx shares are held by insiders. Comparatively, 15.6% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is ACLX or VIR more profitable? Arcellx has a net margin of -25.94% compared to Vir Biotechnology's net margin of -678.40%. Arcellx's return on equity of -8.28% beat Vir Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Arcellx-25.94% -8.28% -5.21% Vir Biotechnology -678.40%-36.71%-31.00% Do analysts prefer ACLX or VIR? Arcellx presently has a consensus price target of $108.46, suggesting a potential upside of 51.31%. Vir Biotechnology has a consensus price target of $35.67, suggesting a potential upside of 398.83%. Given Vir Biotechnology's higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than Arcellx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcellx 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 3.13Vir Biotechnology 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Which has more volatility and risk, ACLX or VIR? Arcellx has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Does the MarketBeat Community prefer ACLX or VIR? Arcellx received 12 more outperform votes than Vir Biotechnology when rated by MarketBeat users. Likewise, 82.93% of users gave Arcellx an outperform vote while only 56.00% of users gave Vir Biotechnology an outperform vote. CompanyUnderperformOutperformArcellxOutperform Votes6882.93% Underperform Votes1417.07%Vir BiotechnologyOutperform Votes5656.00% Underperform Votes4444.00% Which has stronger valuation & earnings, ACLX or VIR? Arcellx has higher revenue and earnings than Vir Biotechnology. Arcellx is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcellx$107.94M36.49-$70.69M-$2.00-35.84Vir Biotechnology$63.71M15.39-$615.06M-$3.82-1.87 Does the media refer more to ACLX or VIR? In the previous week, Arcellx had 1 more articles in the media than Vir Biotechnology. MarketBeat recorded 4 mentions for Arcellx and 3 mentions for Vir Biotechnology. Arcellx's average media sentiment score of 1.31 beat Vir Biotechnology's score of 0.37 indicating that Arcellx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcellx 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vir Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryArcellx beats Vir Biotechnology on 15 of the 19 factors compared between the two stocks. Remove Ads Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIR vs. The Competition Export to ExcelMetricVir BiotechnologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$980.57M$3.08B$5.68B$8.14BDividend YieldN/A1.46%4.40%4.09%P/E Ratio-1.8227.9223.9019.07Price / Sales15.39440.08395.6188.27Price / CashN/A168.6838.1134.64Price / Book0.603.466.834.29Net Income-$615.06M-$71.72M$3.20B$247.56M7 Day Performance-10.18%-2.08%6.58%-0.84%1 Month Performance-25.91%-12.60%-0.31%-9.37%1 Year Performance-33.55%-21.74%13.04%4.01% Vir Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRVir Biotechnology3.6572 of 5 stars$7.15+2.1%$35.67+398.8%-33.6%$980.57M$63.71M-1.82580ACLXArcellx2.1229 of 5 stars$72.18+2.0%$108.46+50.3%+1.5%$3.97B$107.94M-101.6680Positive NewsADMAADMA Biologics2.1087 of 5 stars$16.61-2.4%$22.50+35.4%+207.7%$3.93B$426.45M59.39530Positive NewsZLABZai Lab1.3643 of 5 stars$34.67-4.8%$45.03+29.9%+106.8%$3.80B$398.99M-12.522,175Analyst ForecastNews CoverageGap UpRNAAvidity Biosciences1.876 of 5 stars$30.01-0.9%$65.91+119.6%+27.4%$3.64B$10.90M-10.50190Analyst ForecastNews CoverageSWTXSpringWorks Therapeutics2.9168 of 5 stars$48.41-2.3%$73.20+51.2%+1.7%$3.63B$191.59M-13.91230Short Interest ↓Positive NewsRAREUltragenyx Pharmaceutical4.4232 of 5 stars$37.51-2.9%$93.50+149.3%-17.0%$3.47B$560.23M-5.911,276IMVTImmunovant2.4986 of 5 stars$20.28+1.3%$43.55+114.8%-36.1%$3.44BN/A-7.74120Insider TradePTGXProtagonist Therapeutics2.8335 of 5 stars$56.05+46.1%$58.33+4.1%+89.0%$3.44B$434.43M21.07120Analyst ForecastInsider TradeNews CoverageHigh Trading VolumeSRRKScholar Rock3.5734 of 5 stars$35.20-2.2%$40.43+14.9%+139.4%$3.34B$33.19M-15.00140Insider TradeNews CoverageAKROAkero Therapeutics4.1012 of 5 stars$41.66-1.1%$76.29+83.1%+60.3%$3.33BN/A-11.1430Insider TradeNews Coverage Remove Ads Related Companies and Tools Related Companies ACLX Alternatives ADMA Alternatives ZLAB Alternatives RNA Alternatives SWTX Alternatives RARE Alternatives IMVT Alternatives PTGX Alternatives SRRK Alternatives AKRO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIR) was last updated on 3/16/2025 by MarketBeat.com Staff From Our PartnersElon Warns “America Is Broke”. Trump’s Plan Inside.Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredTrump Shock to change everything Is this Trump’s next major move? Millionaire trading expert Imre Gams has found a bill that directs the Uni...Centurion Publishing | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored[Revealed] Trump’s Plan to Protect Your Savings for the Deep StateDuring Trump's first term, gold skyrocketed 52.89%. And it's already surging before his second. Last yea...Genesis Gold Group | SponsoredAI Boom Takes a Shocking Turn…How to Play AI’s Next BIG Move… It could be the biggest AI money-maker of 2025.Crypto 101 Media | SponsoredForget Trump’s Tariffs, This March Event Is BiggerWhile everyone is distracted by Trump’s tariffs and a potential trade war… There’s something much bigger ha...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
